BioNTech SE (BNTX)

Insider Trading Filed: 2026-05-13

Chief Commercial Officer Annemarie Hanekamp received equity compensation grants totaling 22,655 instruments (12,586 stock options + 10,069 PSUs) on 05/12/2026, representing a standard long-term incentive package rather than discretionary insider buying.
Stock options have an exercise price of EUR 89.38 with a 4-year vesting schedule and 10-year expiration, while PSUs include performance conditions tied to relative stock performance vs. Nasdaq Biotech Index, indicating alignment with company strategic objectives.
The grants vest annually over 4 years starting in 2027, with exercise/vesting in 2030, suggesting management confidence in BioNTech's long-term prospects and retention of key commercial leadership through 2026-2030.
This is a routine equity grant to an executive officer rather than a material insider transaction, with no indication of voluntary purchases or sales that would signal management's conviction about near-term stock valuation.

Insider Trading Filed: 2026-05-13

Chief People Officer Kylie Jimenez received equity compensation grants totaling 18,879 shares (10,488 stock options + 8,391 performance share units) on 05/12/2026, representing standard executive compensation rather than discretionary insider buying.
Stock options have an exercise price of EUR 89.38 with a 4-year vesting schedule and 10-year expiration, indicating BioNTech is using equity incentives to retain leadership through performance-based conditions tied to Nasdaq Biotech Index benchmarks.
Performance share units are conditional on achievement of market-relative performance targets over 4 years, suggesting management compensation is directly aligned with stock performance relative to biotech peers.
This is a routine equity grant filing typical for C-suite executives and carries no signal regarding insider confidence in stock valuation, as these awards are formulaic components of executive compensation packages.

Insider Trading Filed: 2026-05-13

Chief Operating Officer Sierk Poetting received 12,586 stock options with an exercise price of EUR 89.38, vesting annually over 4 years with performance conditions tied to Nasdaq Biotechnology Index relative performance.
Additionally, Poetting was granted 10,069 performance share units (PSUs) that vest over 4 years subject to achievement of market-based performance targets, indicating BioNTech's use of performance-based compensation aligned with shareholder value.
Both grants were awarded on 05/12/2026 and become exercisable in 2030, with options exercisable through 2036, suggesting long-term retention incentives for key leadership during a critical period for the biotech company.
The structure of these grants (options + PSUs with performance conditions) rather than direct share grants indicates BioNTech is tying executive compensation to market performance relative to the broader biotech sector, a prudent governance practice.

Insider Trading Filed: 2026-05-13

Ryan James Timothy Patrick, serving as Chief Legal Officer and Chief Business Officer, received equity grants totaling 22,655 securities (12,586 stock options + 10,069 performance share units) on 05/12/2026, indicating continued executive compensation aligned with long-term performance.
Stock options granted at EUR 89.38 exercise price with a 4-year vesting schedule and 10-year expiration suggest management confidence in BioNTech's future valuation, as options become exercisable only after performance conditions are met.
Performance share units are contingent on achieving market-based targets relative to the Nasdaq Biotechnology Index, indicating the company's compensation strategy ties executive wealth creation directly to biotech sector performance and relative competitiveness.
Both derivative securities have a $0 transaction price, representing standard grant-based compensation rather than open-market purchases, which is routine executive compensation rather than a significant insider buying signal.

Insider Trading Filed: 2026-05-13

CFO Ramon Zapata Gomez received 18,879 stock options and 15,103 performance share units (PSUs) on 05/12/2026, representing standard equity compensation grants with a 4-year vesting schedule.
Options have an exercise price of EUR 89.38 with a 10-year term expiring 05/12/2036, while PSUs are performance-based and tied to outperformance versus the Nasdaq Biotechnology Index relative to the stock price.
This is a routine executive compensation grant rather than discretionary insider buying or selling, indicating no immediate material change in insider confidence about the company's valuation.
The performance-based structure of PSUs suggests management compensation is tied to relative biotech sector performance, aligning executive interests with competitive positioning within the industry.

Insider Trading Filed: 2026-04-23

Chief Operating Officer Sierk Poetting sold 50,000 ordinary shares on April 22, 2026 at $110.56 per share, generating approximately $5.53 million in proceeds, representing a significant insider sale.
The sale was executed pursuant to a Rule 10b5-1 trading plan, indicating this was a pre-arranged transaction rather than opportunistic selling, which reduces concerns about negative insider sentiment.
Poetting retains 399,387 shares held indirectly through Tofino GmbH following the transaction, maintaining substantial beneficial ownership and demonstrating continued confidence in the company despite the sale.

Important Information